Format

Send to

Choose Destination
Cancer Genomics Proteomics. 2018 Sep-Oct;15(5):379-385. doi: 10.21873/cgp.20096.

Pyrosequencing Analysis of MGMT Promoter Methylation in Meningioma.

Author information

1
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway ioannis.panagopoulos@rr-research.no.
2
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
3
Department of Pathology, Oslo University Hospital, Oslo, Norway.
4
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
5
Department of Neurosurgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
6
Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Abstract

BACKGROUND:

Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictor of response to the DNA-alkylating agent temozolomide in patients with glioblastoma.

MATERIALS AND METHODS:

Pyrosequencing analysis was used to determine the MGMT promoter methylation status in 61 meningiomas, to clarify whether it might have a predictive role.

RESULTS:

Only two tumors (3%) had a mean methylation frequency higher than the cut-off value of 10% for the four CpG sites examined.

CONCLUSION:

The methylation of the MGMT promoter is uncommon, or occurs at a low frequency in meningiomas. There is no convincing rationale to test such tumors for their MGMT methylation status in a clinical setting.

KEYWORDS:

MGMT promoter; Meningioma; methylation; predictive value; pyrosequencing

PMID:
30194078
PMCID:
PMC6199576
DOI:
10.21873/cgp.20096
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center